

7:59 P.O.M.

### Normal Immunoglobulin Injection B.P.

1. The first step in the process of identifying a potential threat is to conduct a thorough review of the information available. This includes examining the threat's history, its current status, and the potential impact it could have on the organization. The next step is to assess the threat's vulnerability, which involves identifying the weaknesses in the organization's defenses that the threat could exploit. Finally, the threat's potential impact is evaluated, taking into account the organization's resources and the likelihood of the threat's success.



05742359

1-800-241-9790

2007-2008 Annual Report

2324-2

**GAMMABULIN** is a concentrate of the antibodies present in the immune globulin (IgG) fraction of human plasma. The antibody content in **GAMMABULIN** is ten to twenty times that of normal human plasma. It is

manufactured from pooled plasma.

All plasma units are exclusively obtained from licensed plasmapheresis centers.

For the manufacture of GAMMABULIN only plasma units are used which are non-reactive in tests for HBs-antigen and HIV-antibodies.

~~CANVAXULIN is manufactured by subjecting this source material to a cold ethanol fractionation procedure according to CONN. HIV which was added in defined quantities to samples drawn in the individual steps of the procedure was shown to be partitioned or inactivated, which led to a cumulative decrease in virus titre of at least 21 logs. The use of Immuno's cold ethanol fractionation procedure in the manufacture of, and many years of clinical experience with immunoglobulins, in which no case of anti-HIV seroconversion or viral hepatitis has been reported, make the transmission of viruses causing these infections through this product highly unlikely.~~

In the manufacture of GAMMABULIN, the immunoglobulins in their native form remain unchanged. The biological half-life and the functions depending on intact antibody molecules remain unimpaired.

GAMHABULIN is tested for identity, sterility, freedom from pyrogens, safety and antibody content.